Hims & Hers Launches Personalized Weight Loss Program for UK Women
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Market Expansion: Hims & Hers has launched a comprehensive Weight Loss Program in the UK, providing personalized health management services for eligible women, addressing the urgent needs of 64% of UK adults who are overweight or obese.
- Convenient Services: Through the Hers platform, customers can access doctor-designed weight loss plans, including GLP-1 treatment options, ensuring transparent pricing and personalized support, which enhances customer satisfaction and loyalty.
- Ongoing Support: The program offers 24/7 care team access and resources on nutrition, exercise, and sleep, helping customers develop sustainable lifestyle habits during their weight loss journey, promoting long-term health.
- Strategic Commitment: The GM of Hims & Hers stated that this launch represents a significant commitment to the UK market, aiming to provide sustainable weight management solutions that help people lead healthier lives, reflecting the company's responsibility in addressing the global obesity epidemic.
HIMS.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 46.25 USD with a low forecast of 30.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
2 Buy
6 Hold
3 Sell
Hold
Current: 39.120
Low
30.00
Averages
46.25
High
85.00
Current: 39.120
Low
30.00
Averages
46.25
High
85.00
Barclays
NULL -> Overweight
initiated
$48
2025-12-08
New
Reason
Barclays
Price Target
$48
2025-12-08
New
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target.
Barclays
Overweight
initiated
$48
2025-12-08
New
Reason
Barclays
Price Target
$48
2025-12-08
New
initiated
Overweight
Reason
Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target. With the concerns around the sustainability of the company's compounding strategy now better understood, the firm believes the expectations around the shares have become more reasonable, the analyst tells investors in a research note. The firm added that, looking forward to FY26, it believes the recent addition of other growth drivers help create a more favorable setup for durable growth.
Seaport Research
Buy
downgrade
$66 -> $59
2025-11-04
Reason
Seaport Research
Price Target
$66 -> $59
2025-11-04
downgrade
Buy
Reason
Seaport Research lowered the firm's price target on Hims & Hers to $59 from $66 and keeps a Buy rating on the shares. Quarterly results showed solid growth trends despite near term headwinds, the analyst tells investors.
BofA
Underperform
maintain
$28 -> $32
2025-11-04
Reason
BofA
Price Target
$28 -> $32
2025-11-04
maintain
Underperform
Reason
BofA raised the firm's price target on Hims & Hers to $32 from $28 and keeps an Underperform rating on the shares after the company reported a "mixed" quarter, with revenue and EBITDA exceeding Street and BofA estimates and total subscribers falling below expectations. The firm sees downside risk to 2026 consensus revenue estimates and lowered its own 2026 EBITDA estimates, but rolls its valuation framework from 2025 to 2026, yielding its increased price target.
See All Ratings
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of Hims & Hers' acquisition of Livewell in Canada?
How does YourBio's TAP device improve the blood sampling process for users?
How will Hims & Hers' expansion into Canada impact its stock performance in 2024?
What future revenue growth can Hims & Hers expect from YourBio's technology?